Masayuki Nadai

1.5k citations
106 papers · 1.3k indexed · h-index 20

Masayuki Nadai

103 papers receiving 1.3k citations

Peers

Masayuki Nadai
Comparison fields: 5 of 108
  • Pharmacology 326
  • Pharmacology 343
  • Oncology 500
  • Molecular Medicine 64
  • Pediatrics, Perinatology and Child Health 249
Replace J P Tillement with:
J P Tillement France
George J. Kaloyanides United States
L Balant Switzerland
Jean‐Francois Marier United States
Radim Vrzal Czechia
Guohua An United States
J.P. Tillement France
Myung Gull Lee South Korea
C. A. M. van Ginneken Netherlands
Myung G. Lee South Korea
Masayuki Nadai relative to J P Tillement France J P Tillement's profile →
Citations per field
00.5×1.5×2.1×
J P Tillement · 1×
Citations per year

Countries citing papers authored by Masayuki Nadai

Since Specialization
Citations

This map shows the geographic impact of Masayuki Nadai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayuki Nadai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayuki Nadai more than expected).

Fields of papers citing papers by Masayuki Nadai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayuki Nadai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayuki Nadai. The network helps show where Masayuki Nadai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Masayuki Nadai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Masayuki Nadai Line = papers co-authored together Masayuki Nadai links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20213
2 20182
3 20175
4 201522
5 201514
6 201112
7 20100
8 20102
9 200653
10
20061
11 200534
12 200423
13 200221
14 19986
15 19948
16 19942
17 19923
18 19919
19 199114
20 19905

About Masayuki Nadai

Masayuki Nadai is a scholar working on Pharmacology, Pharmacology and Oncology, having authored 106 papers that have together received 1.3k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (46 papers), Pharmacogenetics and Drug Metabolism (27 papers), Antibiotics Pharmacokinetics and Efficacy (26 papers), Pharmacological Effects and Toxicity Studies (15 papers), Ion Transport and Channel Regulation (9 papers), Analytical Methods in Pharmaceuticals (9 papers), Neonatal Health and Biochemistry (8 papers) and Diet, Metabolism, and Disease (7 papers). The work is most often cited by research in Pharmacology (326 citations), Pharmacology (343 citations) and Oncology (500 citations). Masayuki Nadai has collaborated with scholars based in Japan, China and Australia. Frequent co-authors include Takaaki Hasegawa, Toshitaka Nabeshima, Kenzo Takagi, Miki Katoh, Kenji Takagi, Kiyoyuki Kitaichi, Takafumi Kuzuya, Isao Muraoka, Atsumi Nitta and Akio Itoh. Their work appears in journals such as Biological and Pharmaceutical Bulletin, Antimicrobial Agents and Chemotherapy, Journal of Pharmacy and Pharmacology, Drug Metabolism and Disposition and Xenobiotica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026